Skip to main content
In stock | Targeted Therapy

Masofaniten

Oncology Type Solid Tumour (Prostate)
Drug Class / Mechanism Androgen Receptor Degrader (PROTAC)
No Image
Description

Masofaniten is classified as an Androgen Receptor Degrader (PROTAC), sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Solid Tumour (Prostate)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3